No biomarker	B Acute Lymphoblastic Leukemia	No biomarker	B Acute Lymphoblastic Leukemia	obecabtagene autoleucel Sensitive: A1 - Approval FDA - 1 week (New A1) obecabtagene autoleucel Sensitive : A1 FDA - 1wk	obecabtagene autoleucel Sensitive: A1 - Approval FDA - 1 week obecabtagene autoleucel Sensitive : A1 FDA - 1 week - (New A1)
No biomarker	B Acute Lymphoblastic Leukemia	No biomarker	B Acute Lymphoblastic Leukemia	tisagenlecleucel-T Sensitive: A1 - Approval tisagenlecleucel-T Sensitive : A1	tisagenlecleucel-T Sensitive: A1 - Approval tisagenlecleucel-T Sensitive : A1
No biomarker	Childhood B Acute Lymphoblastic Leukemia	No biomarker	Childhood B Acute Lymphoblastic Leukemia	tisagenlecleucel-T Sensitive: A1 - Approval tisagenlecleucel-T Sensitive : A1	tisagenlecleucel-T Sensitive: A1 - Approval tisagenlecleucel-T Sensitive : A1
BCR-ABL1 fusion	Acute Lymphocytic Leukemia	BCR-ABL1 fusion	Acute Lymphocytic Leukemia	imatinib Sensitive: A1 - Approval imatinib Sensitive : A1	imatinib Sensitive: A1 - Approval imatinib Sensitive : A1
CD22 positive	B Acute Lymphoblastic Leukemia	CD22 positive	B Acute Lymphoblastic Leukemia	inotuzumab ozogamicin Sensitive: A1 - Approval inotuzumab ozogamicin Sensitive : A1	inotuzumab ozogamicin Sensitive: A1 - Approval inotuzumab ozogamicin Sensitive : A1
BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	inotuzumab ozogamicin Sensitive: A1 - Approval inotuzumab ozogamicin Sensitive : A1	inotuzumab ozogamicin Sensitive: A1 - Approval inotuzumab ozogamicin Sensitive : A1
BCR-ABL1 T315I	Acute Lymphocytic Leukemia	BCR-ABL1 T315I	Acute Lymphocytic Leukemia	ponatinib Sensitive: A1 - Approval ponatinib Sensitive : A1	ponatinib Sensitive: A1 - Approval ponatinib Sensitive : A1
No biomarker	Acute Lymphocytic Leukemia	No biomarker	Acute Lymphocytic Leukemia	blinatumomab Sensitive: A1 - Approval blinatumomab Sensitive : A1	blinatumomab Sensitive: A1 - Approval blinatumomab Sensitive : A1
No biomarker	B Acute Lymphoblastic Leukemia	No biomarker	B Acute Lymphoblastic Leukemia	blinatumomab Sensitive: A1 - Approval blinatumomab Sensitive : A1	blinatumomab Sensitive: A1 - Approval blinatumomab Sensitive : A1
BCR-ABL1 fusion	Acute Lymphocytic Leukemia	BCR-ABL1 fusion	Acute Lymphocytic Leukemia	ponatinib Sensitive: A1 - Approval ponatinib Sensitive : A1	ponatinib Sensitive: A1 - Approval ponatinib Sensitive : A1
No biomarker	T Acute Lymphoblastic Leukemia	No biomarker	T Acute Lymphoblastic Leukemia	nelarabine Sensitive: A1 - Approval nelarabine Sensitive : A1	nelarabine Sensitive: A1 - Approval nelarabine Sensitive : A1
BCR-ABL1 fusion	Acute Lymphocytic Leukemia	BCR-ABL1 fusion	Acute Lymphocytic Leukemia	dasatinib Sensitive: A1 - Approval dasatinib Sensitive : A1	dasatinib Sensitive: A1 - Approval dasatinib Sensitive : A1
CD19 positive	Acute Lymphocytic Leukemia	CD19 positive	Acute Lymphocytic Leukemia	blinatumomab Sensitive: A1 - Approval blinatumomab Sensitive : A1	blinatumomab Sensitive: A1 - Approval blinatumomab Sensitive : A1
No biomarker	Acute Lymphocytic Leukemia	No biomarker	Acute Lymphocytic Leukemia	mercaptopurine Sensitive: A1 - Approval mercaptopurine Sensitive : A1	mercaptopurine Sensitive: A1 - Approval mercaptopurine Sensitive : A1
No biomarker	Acute Lymphocytic Leukemia	No biomarker	Acute Lymphocytic Leukemia	vincristine liposomal Sensitive: A1 - Approval vincristine liposomal Sensitive : A1	vincristine liposomal Sensitive: A1 - Approval vincristine liposomal Sensitive : A1
BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	dasatinib Sensitive: A1 - Approval dasatinib Sensitive : A1	dasatinib Sensitive: A1 - Approval dasatinib Sensitive : A1
No biomarker	Childhood B Acute Lymphoblastic Leukemia	No biomarker	Childhood B Acute Lymphoblastic Leukemia	blinatumomab Sensitive: A1 - Approval blinatumomab Sensitive : A1	blinatumomab Sensitive: A1 - Approval blinatumomab Sensitive : A1
CD19 positive	B Acute Lymphoblastic Leukemia	CD19 positive	B Acute Lymphoblastic Leukemia	blinatumomab Sensitive: A1 - Approval blinatumomab Sensitive : A1	blinatumomab Sensitive: A1 - Approval blinatumomab Sensitive : A1
No biomarker	B Acute Lymphoblastic Leukemia	No biomarker	B Acute Lymphoblastic Leukemia	inotuzumab ozogamicin Sensitive: A1 - Approval inotuzumab ozogamicin Sensitive : A1	inotuzumab ozogamicin Sensitive: A1 - Approval inotuzumab ozogamicin Sensitive : A1
No biomarker	B Acute Lymphoblastic Leukemia	No biomarker	B Acute Lymphoblastic Leukemia	brexucabtagene autoleucel Sensitive: A1 - Approval brexucabtagene autoleucel Sensitive : A1	brexucabtagene autoleucel Sensitive: A1 - Approval brexucabtagene autoleucel Sensitive : A1
No biomarker	Acute Lymphocytic Leukemia	No biomarker	Acute Lymphocytic Leukemia	recombinant Sensitive: A1 - Approval recombinant Sensitive : A1	recombinant Sensitive: A1 - Approval recombinant Sensitive : A1
No biomarker	Acute Lymphocytic Leukemia	No biomarker	Acute Lymphocytic Leukemia	pegaspargase Sensitive: A1 - Approval pegaspargase Sensitive : A1	pegaspargase Sensitive: A1 - Approval pegaspargase Sensitive : A1
CD20 positive	Childhood B Acute Lymphoblastic Leukemia	CD20 positive	Childhood B Acute Lymphoblastic Leukemia	rituximab Sensitive: A1 - Approval rituximab Sensitive : A1	rituximab Sensitive: A1 - Approval rituximab Sensitive : A1
No biomarker	Childhood B Acute Lymphoblastic Leukemia	No biomarker	Childhood B Acute Lymphoblastic Leukemia	calaspargase pegol-mknl Sensitive: A1 - Approval calaspargase pegol-mknl Sensitive : A1	calaspargase pegol-mknl Sensitive: A1 - Approval calaspargase pegol-mknl Sensitive : A1
No biomarker	B Acute Lymphoblastic Leukemia	No biomarker	B Acute Lymphoblastic Leukemia	calaspargase pegol-mknl Sensitive: A1 - Approval calaspargase pegol-mknl Sensitive : A1	calaspargase pegol-mknl Sensitive: A1 - Approval calaspargase pegol-mknl Sensitive : A1
BCR-ABL1 V299L	Acute Lymphocytic Leukemia	BCR-ABL1 V299L	Acute Lymphocytic Leukemia	dasatinib Resistant: A2 - Guideline dasatinib Resistant : A2	dasatinib Resistant: A2 - Guideline dasatinib Resistant : A2
BCR-ABL1 F317I	Acute Lymphocytic Leukemia	BCR-ABL1 F317I	Acute Lymphocytic Leukemia	dasatinib Resistant: A2 - Guideline dasatinib Resistant : A2	dasatinib Resistant: A2 - Guideline dasatinib Resistant : A2
BCR-ABL1 T315I	Acute Lymphocytic Leukemia	BCR-ABL1 T315I	Acute Lymphocytic Leukemia	dasatinib Resistant: A2 - Guideline dasatinib Resistant : A2	dasatinib Resistant: A2 - Guideline dasatinib Resistant : A2
BCR-ABL1 fusion	Acute Lymphocytic Leukemia	BCR-ABL1 fusion	Acute Lymphocytic Leukemia	nilotinib Sensitive: A2 - Guideline nilotinib Sensitive : A2	nilotinib Sensitive: A2 - Guideline nilotinib Sensitive : A2
BCR-ABL1 T315I	Acute Lymphocytic Leukemia	BCR-ABL1 T315I	Acute Lymphocytic Leukemia	bosutinib Resistant: A2 - Guideline bosutinib Resistant : A2	bosutinib Resistant: A2 - Guideline bosutinib Resistant : A2
BCR-ABL1 T315I	Acute Lymphocytic Leukemia	BCR-ABL1 T315I	Acute Lymphocytic Leukemia	nilotinib Resistant: A2 - Guideline nilotinib Resistant : A2	nilotinib Resistant: A2 - Guideline nilotinib Resistant : A2
ABL2 fusion	Childhood B Acute Lymphoblastic Leukemia	ABL2 fusion	Childhood B Acute Lymphoblastic Leukemia	dasatinib Sensitive: A2 - Guideline dasatinib Sensitive : A2	dasatinib Sensitive: A2 - Guideline dasatinib Sensitive : A2
IL7R mutation	Childhood B Acute Lymphoblastic Leukemia	IL7R mutation	Childhood B Acute Lymphoblastic Leukemia	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2

Acute Lymphocytic Leukemia

Associations(417)

Associations
(417)